This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Belviq

Arena Pharmaceuticals, Inc.

Drug Names(s): Lorqess, Lorcaserin hydrochloride, Lorcaserin IR, APD356, Venespri

Description: APD356 is a selective agonist of 5-HT2C serotonin receptors, which are concentrated in the hypothalamus, an area of the brain believed to play an important role in regulating food intake and metabolism.

In preclinical studies examining the activity and 5-HT receptor subtype specificity of APD356, APD356 demonstrated a high affinity and specificity for the 5-HT2C receptor, with approximately 15-fold and 100-fold selectivity over the 5-HT2A and 5-HT2B receptors, respectively, and no pharmacologic activity at other serotonin receptors.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

Lorcaserin was originally developed by Arena.

Eisai and Arena
In July 2010, Arena Pharmaceuticals announced that Eisai will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval. As part of the marketing and supply agreement, Arena has granted Eisai exclusive U.S. rights to commercialize lorcaserin. Arena will manufacture lorcaserin at its facility in Switzerland and sell finished product to Eisai for marketing and distribution in the United States.

Under the terms of the agreement, Arena will receive an upfront payment of $50 million from Eisai and, upon regulatory approval and the delivery of product supply for launch, up to an additional $60 million depending on the label (update 6/27/12: will be $60 million following delivery of launch supply and DEA scheduling; an additional $5 million for the DEA scheduling)....See full deal structure in Biomedtracker

Partners: Eisai Co., Ltd. Ildong Pharmaceutical Co., Ltd. CY Biotech Company Ltd. Teva Pharmaceutical Industries Ltd.


Belviq News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug